Taken together, various DPP-4 inhibitors do appear to improve indices of diastolic function in various experimental models of either T2DM or heart failure (Table 3), though it does appear that the impact on heart failure pathogenesis can be influenced by the underlying presence of obesity, insulin resistance and metabolic dysfunction. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.